XSHE
300558
Market cap3.03bUSD
Oct 09, Last price
48.43CNY
1D
1.21%
1Q
-26.47%
Jan 2017
-34.38%
IPO
74.02%
Name
Betta Pharmaceuticals Co Ltd
Chart & performance
P/E
67.15
P/S
5.68
EPS
0.72
Div yield, %
0.42%
Shrs. gr., 5y
0.55%
Rev. gr., 5y
14.05%
Revenues
3.61b
+24.81%
Net income
305m
-24.15%
CFO
911m
+0.01%
Dividend
Jun 09, 20260.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and Ensartinib hydrochloride, an anaplastic lymphoma kinase (ALK) inhibitor, both utilized in the management of non-small-cell lung cancer. Founded in 2003, the firm is headquartered in Hangzhou, China.
Key people
Yinxiang Wang
President
Sulan Xu
Chief Financial Officer
Fenlai Tan
Vice President
Lieming Ding
Chairman of the Board, Chief Executive Officer, General Manager · since 2013
Lingxi Wu
Secretary of the Board · since 2020
Lieming Ding
Executive Officer, Chairman of the Boar
Shizhe Ding
Staff Elected Director · since 2025
Jianxun Fan
Chief Financial Officer, Vice President, Director · since 2021
Yongjun Liu
Director · since 2025
Li Mao
President - R&D, Chief Medical Officer, Director · since 2025
Jia Tong
President - Public Administration, Director · since 2021
Jiang Wan
Chief Operating Officer, Senior Vice President, Director · since 2020
Tian Xu
Director · since 2022
Xiaodong Zhang
Vice Chairman
Xinqi Huang
Independent Director · since 2021
Jiajia Xiao
Independent Director · since 2021
Jianwei Xuan
Independent Director · since 2025
Jianliang Ye
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||